...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of ocular pharmacology and therapeutics: The official journal of the Association for Ocular Pharmacology and Therapeutics >Intravitreal bevacizumab injection therapy for persistent macular edema after idiopathic macular epiretinal membrane surgery.
【24h】

Intravitreal bevacizumab injection therapy for persistent macular edema after idiopathic macular epiretinal membrane surgery.

机译：玻璃体腔注射贝伐单抗治疗特发性黄斑视网膜前膜手术后持续性黄斑水肿。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

PURPOSE: The purpose of this study was to evaluate the effects of intravitreal bevacizumab (ivBe) injection in patients with persistent macular edema after macular epiretinal membrane (ERM) removal. METHODS: This retrospective study included 26 patients (26 eyes) with marked macular edema after complete removal of idiopathic macular ERM who received single ivBe injection (12 patients) or no treatment (controls, 14 patients). Main outcome measurements were central macular thickness (CMT) and best-corrected visual acuity (BCVA). RESULTS: In the ivBe group, the mean CMT+/-standard deviation (SD) changed significantly from 323+/-43 mum at baseline to 306+/-41, 301+/-42, and 296+/-41 mum at weeks 4, 8, and 12, respectively, after treatment (P= 0.025, <0.0001, and <0.0001, respectively). The BCVA in logarithm of the minimum angle of resolution (logMAR)+/-SD did not change significantly from 0.50+/-0.15 at baseline to 0.46+/-0.11, 0.44+/-0.14, 0.44+/-0.14, and 0.42+/-0.13 at weeks 1, 4, 8, and 12, respectively, after treatment (P>0.05 for all). In the control group, the mean CMT+/-SD changed significantly from 326+/-32 mum at baseline to 314+/-29, 308+/-29, and 307+/-30 mum at weeks 4, 8, and 12, respectively, after treatment (P=0.002, <0.0001, and <0.0001, respectively). The BCVA in logMAR+/-SD did not change significantly from 0.52+/-0.22 at baseline to 0.49+/-0.20, 0.47+/-0.22, 0.45+/-0.16, and 0.47+/-0.23 at modified weeks 1, 4, 8, and 12, respectively, after treatment (P>0.05 for all). No significant differences were found for CMT or BCVA between the ivBe group and the control group at baseline and at any checkpoints after treatment (P>0.05 for all). CONCLUSION: ivBe injection therapy provided no beneficial effects on CMT or visual acuity improvement for eyes with persistent macular edema after idiopathic macular ERM removal.
机译：目的：本研究的目的是评估玻璃体腔注射贝伐单抗（ivBe）对黄斑前膜（ERM）去除后持续性黄斑水肿的影响。方法：这项回顾性研究包括26例（26眼）完全去除特发性黄斑ERM后出现明显黄斑水肿的患者，他们接受了单次ivBe注射（12例）或未接受任何治疗（对照组14例）。主要结局指标为中央黄斑厚度（CMT）和最佳矫正视力（BCVA）。结果：在ivBe组中，平均CMT +/-标准偏差（SD）从基线时的323 +/- 43微米显着变化为第306周的306 +/- 41、301 +/- 42和296 +/- 41毫米处理后分别为4、8和12（分别为P = 0.025，<0.0001和<0.0001）。最小分辨率角（logMAR）+/- SD的对数的BCVA从基线的0.50 +/- 0.15变为0.46 +/- 0.11、0.44 +/- 0.14、0.44 +/- 0.14和0.42没有明显变化治疗后第1、4、8和12周分别为+/- 0.13（对于所有患者，P> 0.05）。在对照组中，平均CMT +/- SD从基线时的326 +/- 32微米显着变化到第4、8和12周时的314 +/- 29、308 +/- 29和307 +/- 30毫米。分别在治疗后（P = 0.002，<0.0001和<0.0001）。 logMAR +/- SD中的BCVA从基线的0.52 +/- 0.22显着变化到第1、4周修改后的0.49 +/- 0.20、0.47 +/- 0.22、0.45 +/- 0.16和0.47 +/- 0.23治疗后分别为8、8和12（所有P> 0.05）。在基线和治疗后任何检查点，ivBe组和对照组之间的CMT或BCVA均无显着差异（所有P均> 0.05）。结论：ivBe注射疗法对特发性黄斑ERM去除后持续性黄斑水肿的眼睛的CMT或视敏度没有改善。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号